By Andy Choi
Mazor Robotics, an Israel-based spine technology manufacturer, has seen a large increase in sales after the FDA recently approved marketing of the Emerald spinal-implant system.
Shares in Mazor Robotics increased the most in more than four months after the FDA approval. The shares climbed 7.3 percent, the biggest gain since Sept. 1, to 10.80 shekels at the 4:30 p.m. close in Tel Aviv. The stock has gained 31 percent over the past year, giving the company a market value of $59 million (213 million shekels).
The company plans on marketing the implants in the second half of 2011, according to the report. Mazor Surgical Technologies received FDA approval for the combined Spine-Assist navigation and C-InSight imaging system for use during treatment of spinal compression fractures as well as other vertebral surgical problems, according to a medGadget.com news report.
SpineAssist, currently used by physicians at the Texas Back Institute and Texas Health Plano in Plano, Texas, is a miniature device mounted above the patient's spine and a workstation with software allowing the surgeon to pre plan the surgery using the 3D imaging technology. Physicians can position the implants within each disc on the AP, lateral and axial plane. The workstation is connected to a C-Arm.
The C-InSight is an add-on to the C-Arm, converting 2D scans to 3D images intra-operatively. This technology could replace post-operative CT scans, according to the report.